High-Frequency Microsatellite Instability is Associated with Defective DNA Mismatch Repair in Human Melanoma  by Alvino, Ester et al.
High-Frequency Microsatellite Instability is Associated with
Defective DNA Mismatch Repair in Human Melanoma
Ester Alvino, Giancarlo Marra,* Elena Pagani,² Sabrina Falcinelli,² Rita Pepponi,² Claudia Perrera,*
Ritva Haider,* Daniele Castiglia,³ Giulio Ferranti,§ Enzo Bonmassar,² Josef Jiricny,* Giovanna Zambruno,³
and Stefania D'Atri²
Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy; *Institute of Medical Radiobiology, University of ZuÈrich, Switzerland;
²Laboratory of Pharmacology, ³Laboratory of Molecular and Cell Biology, and §Histopathology Service, Istituto Dermopatico dell'Immacolata,
IRCCS, Rome, Italy
Hereditary nonpolyposis colorectal cancers and a
steadily increasing number of sporadic tumors dis-
play microsatellite instability. In colorectal tumors,
high-frequency microsatellite instability is strictly
associated with inactivation of the DNA mismatch
repair genes hMSH2, hMLH1, or hPMS2, whereas
mutations in the mismatch repair gene hMSH6 have
been identi®ed in a subset of tumors with low-fre-
quency microsatellite instability. In addition to
epithelial tumors of the colon, endometrium, and
ovary, microsatellite instability has been reported to
occur also in sporadic melanoma. The relationship
between microsatellite instability and mismatch
repair in melanoma cells, however, has not been
investigated so far. In this study, we analyzed micro-
satellite instability, mismatch repair activity, and
expression of the hMSH2, hMSH6, hMLH1, and
hPMS2 proteins in ®ve melanoma cell lines and in
tumor specimens from which the cells were derived.
Four cell lines displayed normal levels of mismatch
repair activity and expressed all the mismatch repair
proteins. The extracts of the ®fth cell line lacked the
hMLH1 and hPMS2 proteins, and were correspond-
ingly de®cient in the repair of DNA mismatches.
This line displayed high-frequency microsatellite
instability, whereas the four mismatch-repair-pro®-
cient cell lines displayed either no or low-frequency
microsatellite instability. These ®ndings could be
con®rmed in the tumor specimens, in that only the
tumor that did not express hMLH1 and hPMS2 dis-
played high-frequency microsatellite instability. Our
data are consistent with the hypothesis that in mela-
noma, similarly to epithelial tumors, only the high-
frequency microsatellite instability phenotype is
strictly dependent on a defective mismatch repair
system. Further studies on a large series of tumor
specimens are required to establish the frequency of
mismatch repair loss in human melanoma. Key
words: cancer/genomic instability/loss of heterozygosity. J
Invest Dermatol 118:79±86, 2002
M
icrosatellites are short sequence elements that
consist of mononucleotide to hexanucleotide
motifs iterated several times (Tautz, 1993). They
occur randomly throughout the genomes, in-
cluding gene coding regions, in many organisms.
In man, microsatellite repeats have been found, among others, in
TGFbRII (Markowitz et al, 1995), IGFIIR (Souza et al, 1996),
BAX (Rampino et al, 1997), and E2F-4 (Yoshitaka et al, 1996)
genes, the products of which play important roles in controlling cell
growth and apoptosis.
In the past few years it has been shown that microsatellite repeat
lengths in tumor tissues often vary as a result of insertion or deletion
mutations that were acquired during DNA replication. This
phenomenon, termed microsatellite instability (MSI), was originally
described in tumors from patients with hereditary nonpolyposis
colorectal cancer (HNPCC) syndrome (Aaltonen et al, 1993; Ionov
et al, 1993; Thibodeau et al, 1993), a familial form of colon cancer
that also predisposes to endometrial, gastric, renal, ureteral, and
ovarian malignancies (reviewed in Marra and Boland, 1995; Kinzler
and Vogelstein, 1996; Lynch et al, 1996). At least 70% of HNPCC
kindred harbor germline mutations in the genes encoding the
mismatch repair (MMR) protein hMSH2, hMLH1, or hPMS2
(HNPCC database at http://www.nfdht.nl). The MSI phenotype
of tumors arising in these patients is attributable to somatic
inactivation of the wild-type allele of the MMR gene. Indeed, the
MMR system recognizes, through the heterodimer hMSH2/
hMSH6 (also called hMutSa), misincorporated bases and insertion/
deletion loops, which frequently occur during DNA duplication.
The repair process proceeds with the essential participation of the
heterodimer hMLH1/hPMS2 (also called hMutLa) and other
proteins (reviewed in Modrich, 1997; Jiricny and NystroÈm-Lahti,
2000). Due to their repetitive structure, which favors strand
slippage, microsatellites are particularly prone to replication errors
and therefore show instability in cells with a defective MMR.
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MSI is also found in sporadic malignancies (reviewed in
Eshleman and Markowitz, 1995), ranging from colorectal
(Thibodeau et al, 1993; Kim et al, 1994; Kinzler and Vogelstein,
1996), endometrial (Risinger et al, 1993; MacDonald et al, 2000),
and pancreatic tumors (Han et al, 1993; Yamamoto et al, 2001) to
head and neck squamous cell carcinomas (Field et al, 1995) and
small cell lung cancers (Merlo et al, 1994).
Tumors with MSI can be generally classi®ed into two groups:
those displaying high-frequency MSI (H-MSI) (MSI in > 30%±
40% of the loci examined) and those with low-frequency MSI (L-
MSI) (MSI in < 30%±40% of the loci examined) (Boland et al,
1998; Thibodeau et al, 1998). The H-MSI phenotype is found in
the majority of HNPCC tumors and in a subset of sporadic cancers
with MSI. In HNPCC families it is linked to mutations in hMSH2,
hMLH1, or hPMS2, whereas the main mechanism of MMR
inactivation in sporadic tumors appears to involve transcriptional
silencing of hMLH1 (Kane et al, 1997; Esteller et al, 1998; Leung et
al, 1999). The L-MSI phenotype has been found mainly in sporadic
tumors, as well as in a minority of HNPCC cancers. The molecular
mechanisms underlying the L-MSI phenotype have not been
entirely elucidated. L-MSI of mononucleotide tracts appears to be
associated with mutations of the hMSH6 MMR gene in tumors of
several atypical HNPCC kindred (Akiyama et al, 1997; Wijnen et
al, 1999; Wu et al, 1999), but the majority of L-MSI colorectal
tumors, familial or sporadic, do not have alterations in this gene
(Percesepe et al, 1998; Kolodner et al, 1999; Parc et al, 2000; Huang
et al, 2001).
The presence of MSI in cutaneous melanomas has to date been
addressed by only a few studies, with MSI percentages varying from
2% to 30% in primary melanomas (Peris et al, 1995; Quinn et al,
1995; Richetta et al, 1997; Talwalkar et al, 1998; Birindelli et al,
2000) and from 20% to 70% in metastatic lesions (Tomlinson et al,
1996; Richetta et al, 1997). Although the majority of the studied
melanomas displayed MSI at only one out of six or 10 loci
examined, and might therefore be classi®ed as L-MSI, the H-MSI
phenotype was detected in a few tumors (Tomlinson et al, 1996;
Richetta et al, 1997; Birindelli et al, 2000). The latter results implied
loss of MMR through mutation of the hMSH2, hMLH1, or hPMS2
genes, but none of these studies evaluated the expression of MMR
proteins in the tumor specimens, and search for mutations in
hMSH2 and hMLH1 was unsuccessful (Tomlinson et al, 1996).
There are thus no data documenting a relationship between loss of
MMR and MSI in melanoma.
In this study, MSI, MMR activity, and expression of MMR
proteins were evaluated in ®ve human melanoma cell lines. We
found that the H-MSI but not the L-MSI phenotype was associated
with loss of MMR function. This result could be con®rmed also in
the melanoma specimens from which the ®ve cell lines were
derived.
MATERIALS AND METHODS
Cell lines Five human melanoma cell lines established in our
laboratory were used in this study. GR-Mel was derived from a primary
skin melanoma, CN-Mel and CR-Mel were obtained from lymph nodal
metastases, whereas PR-Mel and SN-Mel were established from a
cutaneous and a subcutaneous metastasis, respectively.
The MMR-pro®cient human B lymphoblastoid cell line TK6 was a
generous gift of W.G. Thilly (Massachusetts Institute of Technology,
Cambridge, MA). The MMR-de®cient human colorectal adenocarci-
noma cell lines HCT116 and LoVo were obtained from American Type
Culture Collection (Rockville, MD). HCT116 cells have a hemizygous
nonsense mutation in the hMLH1 gene (Papadopoulos et al, 1994; Umar
et al, 1994), whereas LoVo cells are homozygous for a partially deleted
hMSH2 gene (Umar et al, 1994).
The melanoma and TK6 cells were cultured in RPMI-1640 (Hyclone
Europe, Cramlington, U.K.) supplemented with 10% heat-inactivated
fetal bovine serum (Hyclone Laboratories, Logan, UT), 2 mM L-
glutamine, and antibiotics (Gibco BRL, Paisley, U.K.), whereas the
HCT116 and LoVo cell lines were maintained in modi®ed McCoy's 5A
medium (Gibco) supplemented as described above.
For each melanoma cell line the corresponding paraf®n-embedded
tumor and cryopreserved matched peripheral blood mononuclear cells,
collected from the patient at the time of surgery, were available. All
biologic material was obtained with the patients' informed consent. No
patient was known to have HNPCC or Muir±Torre syndrome or to
have a relative with either one of these hereditary diseases.
Table I. Characteristics of microsatellite markers used for MSI and LOH analysis
Locus Chromosome location Primer sequence 5¢®3¢a PCR Tmb Size (bp)c Reference
BAT16 7p22 TCCACTGTGTCTTTATTAGG 55 80±100 Zhou et al (1997)
AAACCGTACTCTTCACACAC
BAT21 3p22±23 ATACTTCTTATTCTGAGTCT 55 80±100 Zhou et al (1997)
ATTTAACCATCTCCCCAGAG
BAT25 4q12 TCGCCTCCAAGAATGTAAGT 55 »90 Dietmaier et al (1997)
TCTGCATTTTAACTATGGCTC
BAT26 2p16 TGACTACTTTTGACTTCAGCC 60 80±100 Dietmaier et al (1997)
AACCATTCAACATTTTTAACCC
BAT40 1p13.1 ATTAACTTCCTACACCACAAC 50 80±100 Dietmaier et al (1997)
GTAGAGCAAGACCACCTTG
D2S71 2q12±14 GCTTGTTACATTGTTGCTTC 55 138±154 Peris et al (1995)
TCTAACCCTTTGGCCATTTG
D2S123 2p16 ACATTGCTGGAAGTTCTGGC 60 100±140 Liu et al (1996)
CCTTTCTGACTTGGATACCA
D3S1317 3p25±26 TACAAGTTCAGTGGAGAACC 60 159±171 Peris et al (1995)
CCTCCAGGCCATACACAGTCA
D5S346 5q21±22 ACTCACTCTAGTGATAAATCG 60 96±122 Dietmaier et al (1997)
AGCAGATAAGACAGTATTACTAGTT
D11S904 11p13±14 ATGACAAGCAATCCTTGAGC 60 185±201 Dietmaier et al (1997)
CTGTGTTATATCCCTAAAGTGGTGA
D17S250 17q11.2±12 GGAAGAATCAAATAGACAAT 50 151±169 Dietmaier et al (1997)
GCTGGCCATATATATATTTAAACC
D18S34 18q12.2±12.3 CAGAAAATTCTCTCTGGCTA 55 103±119 Peris et al (1995)
CTCATGTTCCTGGCAAGAAT
aAll primer sequences, except those relative to BAT16, BAT21, and D5S346, are also available in the Genome DataBase.
bTemperature of annealing expressed in °C.
cApproximate size of ampli®ed DNA.
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Monoclonal antibodies (MoAb) Mouse MoAb against hMSH2
(clone GB12) and hPMS2 (clone 9) were purchased from Oncogene
Research Products (Boston, MA); mouse MoAb against hPMS2 (clone
A16-4) and against hMLH1 (clone G168-15) were obtained from BD
PharMingen (Heidelberg, Germany); mouse MoAb against hMSH6
(clone 44) was purchased from BD Transduction Laboratories
(Heidelberg, Germany); mouse MoAb against hMSH6 (clone 2D4) has
been described previously (Marra et al, 1998); MoAb against a-tubulin
(clone DM1A) was from Amersham Pharmacia Biotech
(Buckinghamshire, U.K.).
DNA extraction DNA extraction from peripheral blood mononuclear
cells and from the melanoma cell lines was performed using standard
methods (Miller et al, 1988). To isolate DNA from paraf®n-embedded
melanoma specimens, a 4 mm section of each sample was stained with
hematoxylin and eosin to identify the areas of tumor consisting of more
than 80% melanoma cells. Four or ®ve additional 10 mm serial sections
were then mounted on slides and the selected tumor areas were carefully
microdissected with a scalpel. The microdissected tissue was subsequently
scraped, suspended in 10±50 ml of digestion buffer containing 10 mM
Tris±HCl, pH 8, 0.1 M ethylenediamine tetraacetic acid (EDTA), 0.5%
sodium dodecyl sulfate (SDS), and 200 mg per ml proteinase K, and
incubated at 50°C for 3 h. DNA was extracted with an equal volume of
phenol:chloroform:isoamyl alcohol (25:24:1), and precipitated with 0.3
M sodium acetate in 100% ethanol. In one case, tumor DNA was
heavily contaminated with melanine and had to be puri®ed with the
Wizard DNA Clean-up System (Promega, Madison, WI).
Microsatellite analysis Twelve different microsatellite loci were
analyzed. Among these, ®ve were mononucleotide repeats (BAT16,
BAT21, BAT25, BAT26, and BAT40) and seven were (CA)n
dinucleotide repeats (D2S71, D2S123, D3S1317, D5S346, D11S904,
D17S250, D18S34). Chromosome location, polymerase chain reaction
(PCR) primers, annealing temperature, and length of ampli®ed DNA for
each marker are listed in Table I. Primer sequences were from the
Genome DataBase (http://gdbhttp://www.gdb.org/) or as published by
others (Table I). The microsatellite loci were chosen to comprise the set
(BAT25, BAT26, D2S123, D5S346, D17S250) recommended for
examining MSI in colorectal tumors (Boland et al, 1998), as well as
additional markers frequently used for MSI analysis in colorectal cancers
(BAT16, BAT21, BAT40, D11S904) (Dietmaier et al, 1997; Zhou et al,
1997) and loci for which instability has been described in melanoma by
other authors (D2S71, D18S34, D3S1317) (Peris et al, 1995; Richetta et
al, 1997).
PCR ampli®cation of genomic DNA was performed with an initial
denaturation step of 3 min at 98°C linked to 35 cycles for 30 s at 94°C,
60 s at the primer-speci®c annealing temperature (Table I), and 30 s at
73°C, followed by a ®nal extension step of 5 min at 73°C. The PCRs
and electrophoretic runs were performed as previously described (Alvino
et al, 2000). The gels were then ®xed, dried, and exposed to X-ray ®lm
(Biomax MR, Kodak, Rochester, NY). All microsatellite markers show-
ing MSI or loss of heterozygosity (LOH) were analyzed two or more
times.
De®nition of MSI and LOH MSI is de®ned as a difference in length
(due to insertion or deletion) of the ampli®ed microsatellite markers
between the normal and tumor tissue of the same individual (Boland et
al, 1998). The melanoma cell lines and tumor specimens were de®ned as
having H-MSI or L-MSI phenotype when they displayed instability in >
30%±40% or in < 30%±40% of the markers tested, respectively (Boland
et al, 1998). Tumors and cell lines lacking MSI were de®ned as
microsatellite stable.
LOH was de®ned as a signi®cant attenuation (>50%) or loss of one
allele in tumor cells.
Preparation of nuclear extracts for in vitro MMR
assay Exponentially growing melanoma cells were washed in
phosphate-buffered saline and used for preparation of nuclear extracts as
described by Holmes et al (1990) with minor modi®cations. The isolated
nuclei were resuspended in cold extraction buffer [50 mM HEPES±
KOH, pH 7.5, 10% sucrose, 1 mM phenylmethylsulfonyl ¯uoride
(PMSF), 0.5 mM dithiothreitol (DTT), 1 mg per ml leupeptin] in the
smallest volume possible. 0.031 vol of 5 M NaCl was then added and
the mixture was rotated for 1 h at 4°C. The nuclear debris was pelleted
at 14,500 3 g for 20 min at 4°C. The supernatant was dialyzed for 2 h
at 4°C against dialysis buffer (25 mM HEPES±KOH, pH 7.6, 50 mM
KCl, 0.1 mM EDTA, 10% sucrose, 0.1% PMSF, 2 mM DTT, 1 mg per
ml leupeptin). After dialysis, the extract was clari®ed by centrifugation at
20,000 3 g for 15 min at 4°C. The nuclear extract was then stored in
small aliquots at ±80°C. The conductivity of the extracts was measured
and the salt concentration was calculated based on a standard KCl
concentration curve.
Construction of the MMR substrate A circular DNA heteroduplex
(3.2 kb) suitable for the in vitro mismatch repair reaction was constructed
essentially as described previously (Lahue et al, 1989; Holmes et al, 1990).
In brief, two oligonucleotides, 5¢-GGCCGCTCCCTGCAGGGACTA-
GATCTCCCTCAAGTACTA-3¢ and 5¢-GGCCGCTCCCTGCAGG-
GACTGGATCTCCCTCAAGTACTA-3¢, differing in one position
(denoted in bold), were cloned between the HindIII and NotI restriction
sites of phagemid pGEM13Zf(+). The ®rst oligonucleotide contains a
unique BglII restriction site (solid underline), which is mutated in the
second oligonucleotide (dotted underline). The resulting plasmids were
called pGemA/T (sensitive to BglII) and pGemG/C (resistant to BglII).
Viral single-strand DNA was isolated from XL1Blue Escherichia coli strain
transfected with pGemA/T and superinfected with M13KO7 helper
phage. The replicative form of pGemG/C, isolated from E. coli strain
DH5a, was linearized with the restriction enzyme BanII and mixed with
10-fold molar excess of ssDNA, followed by alkaline denaturation and
annealing. The remaining linear homoduplex DNA was removed by
hydrolysis with plasmid-safe ATP-dependent DNase (Epicentre
Technologies, WI), and the excess ssDNA was removed by BND-
cellulose chromatography. The resulting heteroduplex DNA, also called
pGemG/T, contains a unique G/T mismatch located 369 bp
downstream of the single-strand incision.
In vitro MMR assay The assays were carried out as described
previously (Lahue et al, 1989; Holmes et al, 1990) with minor
modi®cations. The reaction mixtures (20 ml) contained 0.02 M Tris±
HCl, pH 7.6, 5 mM MgCl2, 1 mM glutathione, 50 mg per ml bovine
serum albumin, 0.1 mM each dNTP, 1.5 mM ATP, 0.04 M KCl, 75 ng
of heteroduplex DNA, and 75 mg of nuclear cell extract. As the nuclear
extracts contain a variable amount of KCl, determined by the
measurement of the conductivity, all the reaction mixtures were adjusted
to 110 mM KCl. Reactions were incubated at 37°C for 30 min and
were terminated by the addition of 30 ml of stop solution (25 mM
EDTA, 0.67% SDS, 50 mg per ml proteinase K) for 15 min at 37°C.
After phenol extraction and ethanol precipitation, the extent of mismatch
correction was determined. The presence of a G/T mismatch makes
the pGEM phagemid refractory to cleavage with the restriction
endonuclease BglII. The repair reaction converts the G/T heteroduplex
to an A/T homoduplex, such that the repair ef®ciency can be estimated
from the amount of phagemid DNA cleaved by BglII. Thus, DNA
molecules were linearized with BsaI and treated with BglII. The presence
of two fragments (1833 bp and 1360 bp) generated from the double
restriction is indicative of G/T to A/T repair. The repair ef®ciency was
expressed as fmol DNA cleaved by BglII in 30 min of incubation (fmol
per 30 min).
Complementation experiments were performed by adding 0.1 mg of
recombinant hMutSa (hMSH2/hMSH6 heterodimer) or hMutLa
(hMLH1/hPMS2 heterodimer) to the reaction mixture (Iaccarino et al,
1998).
Western blotting Cells were suspended in lysis buffer [50 mM Tris±
HCl, pH 8.0, 350 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM
PMSF, 2 mg per ml aprotinin, 0.7 mg per ml pepstatin, 1 3 protease
inhibitor cocktail complete EDTA-free (Roche, Mannheim, Germany)]
for 30 min on ice and centrifuged (3 min at 12,000 3 g), and the
supernatant was recovered. Eighty micrograms of protein per sample
were run in 7% SDS-polyacrylamide gels. The proteins were then
transferred to supported nitrocellulose membranes (Hybond-C,
Amersham Pharmacia Biotech). The blots were ®rst blocked in 50 mM
Tris±HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20, 5% nonfat dry milk
for 1 h at 37°C, and then incubated (overnight at 4°C) with the
following primary MoAb: anti-hMSH2 (1 mg per ml), anti-hMSH6
(clone 2D4, 12 mg per ml), anti-hMLH1 (0.1 mg per ml), anti-PMS2
(clone 9, 0.5 mg per ml), anti-a-tubulin (0.1 mg per ml). The latter
MoAb was used as an internal standard for loading. Immunodetection
was carried out by using a horseradish-peroxidase-linked antimouse
secondary antibody and ECL detection reagents (Amersham Pharmacia
Biotech).
Immunohistochemistry Four-micron serial sections from paraf®n
blocks were mounted on silanized slides and deparaf®nized. Antigen
retrieval was obtained by heating the sections in a pressure cooker at
120°C for 2 min in 10 mM citrate-buffered solution (pH 6.0).
Peroxidase blocking reagent (Dako, Glostrup, Denmark) and goat serum
(Dako) were sequentially used to suppress nonspeci®c staining due to
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endogenous peroxidase activity and nonspeci®c binding of MoAb,
respectively. Incubations with primary MoAb were performed as follows:
anti-hMSH2, 24 h at 4°C, 1 mg per ml; anti-hMSH6 (clone 44), 2 h at
room temperature, 4 mg per ml; anti-hMLH1, 1 h at room temperature,
1.2 mg per ml; anti-hPMS2 (clone A16-4), 24 h at 4°C, 3 mg per ml.
After washing, antimouse secondary antibodies conjugated to a
peroxidase-labeled polymer (Dako EnVision+ kit) were applied for
30 min at room temperature, and the peroxidase activity was developed
by incubation with 3,3¢-diaminobenzidine chromogen solution (Dako).
The sections were then lightly counterstained with hematoxylin.
RESULTS
MMR activity and microsatellite alterations in melanoma
cell lines To see whether MSI in human melanoma is associated
with a defective MMR we examined MMR activity, MMR
protein expression, and MSI in ®ve melanoma cell lines established
in our laboratory. The MMR-pro®cient lymphoblastoid cell line
TK6 was used as a positive control for the in vitro MMR assay and
for the Western blot analyses.
As shown in Fig 1, nuclear extracts obtained from CN-Mel,
CR-Mel, GR-Mel, and SN-Mel cell lines were all able to repair
the G/T mismatch present in the heteroduplex DNA used as
substrate, albeit with different ef®ciencies. In contrast, no repair
activity was detected in the extracts of PR-Mel cells. Addition of
puri®ed recombinant hMutLa, but not hMutSa, to these extracts
restored the mismatch repair activity to 90% (data not shown),
which implied a defect in hMLH1 or hPMS2.
Expression of the hMSH2, hMSH6, hMLH1, and hPMS2
proteins in the ®ve cell lines was examined by Western blot.
Figure 2 shows that the four MMR-pro®cient cell lines expressed
all the proteins, whereas hMLH1 and hPMS2 were not detectable
in the MMR-de®cient extracts of the PR-Mel cell line.
To determine the MSI status of these cell lines, their DNA was
extracted and 12 different microsatellite loci were ampli®ed by
PCR. The results were compared with those obtained using DNA
extracted from peripheral blood mononuclear cells of the corres-
ponding patient. As illustrated in Table II and Fig 3, the four
MMR-pro®cient cell lines either showed no MSI (SN-Mel) or
displayed MSI only at a single locus among the mononucleotide
repeats with no MSI at the dinucleotide markers (8.3% of the loci
tested) (CN-Mel, CR-Mel, and GR-Mel). In contrast, the MMR-
de®cient cell line PR-Mel displayed widespread MSI at both
monucleotide and dinucleotide markers (42% of the loci tested). In
this cell line, the microsatellite BAT21, which was reported to be
essentially dimorphic, with an eight-nucleotide size difference
between the two alleles (Zhou et al, 1997), showed both LOH and
MSI. The band pattern of BAT21 in PR-Mel is compatible with
either a loss of the longer allele and a limited shift of the shorter
one, or the loss of the shorter allele and a marked size reduction of
the longer one. LOH was also detected at D11S904 in CN-Mel
and SN-Mel and at D17S250 in GR-Mel.
Microsatellite alterations and MMR protein expression in
melanoma specimens The MSI status and MMR protein
expression were then analyzed in the tumor specimens from which
the ®ve melanoma cell lines were derived.
The microsatellite markers displaying MSI or LOH in CN-
Mel, CR-Mel, and PR-Mel cell lines exhibited similar alter-
ations in the matched tumors (Fig 3). In contrast, MSI at
BAT25 and LOH at D17S250 were not detected in the
Figure 1. MMR activity in human melanoma cell lines. A circular
heteroduplex substrate containing a single G/T mismatch was incubated
with extracts of the ®ve melanoma cell lines as described in Materials and
Methods. MMR activity is expressed in terms of fmol of DNA substrate
repaired in 30 min. Each value represents the mean 6 SEM of three
experiments. Extracts of the MMR-pro®cient TK6 cells were used as a
positive control.
Figure 2. Expression of MMR proteins in human melanoma cell
lines. 80 mg (TK6 and melanoma cells) or 50 mg (HCT116 and LoVo
cells) of the whole cell extracts were subjected to electrophoresis on a
7% SDS-polyacrylamide gel. The proteins were transferred to a
nitrocellulose membrane and incubated with MoAb against hMSH2,
hMSH6, hMLH1, or hPSM2. Incubation with anti-a-tubulin MoAb
was performed as a loading control. The immune complexes were
visualized using ECL. LoVo cells, expressing hMLH1 and hPSM2 but
not hMSH2 and hMSH6, and HCT116 cells, expressing hMSH2 and
hMSH6 but not hMLH1 and hPMS2, were used as negative controls.
Table II. Microsatellite alterations in human melanoma
cell lines
Locus
Cell line
CN-Mel CR-Mel GR-Mel PR-Mel SN-Mel
BAT16 ±a ± ± ± ±
BAT21 ± ± ± MSI/LOH ±
BAT25 ± ± MSI MSI ±
BAT26 ± ± ± ± ±
BAT40 MSI MSI ± ± ±
D2S71 ± ± ± ± ±
D2S123 ± ± ± ± ±
D3S1317 ± ± ± MSI ±
D5S346 ± ± ± ± ±
D11S904 LOH ± ± ± LOH
D17S250 ± ± LOH MSI ±
D18S34 ± ± ± MSI ±
a±, absence of microsatellite alterations.
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melanoma specimen from which the GR-Mel cell line was
derived (Fig 3). These ®ndings suggest that these alterations
arose in cell culture, or that the cell line was derived from a
subset of cells already possessing MSI at BAT25 and LOH at
D17S250. The D11S904 microsatellite was not ampli®able in
the tumor specimen SN; thus the sample was not informative.
According to these results, CR and CN melanomas were
classi®ed as having an L-MSI phenotype, whereas an H-MSI
phenotype was assigned to the PR tumor. The GR and SN
melanoma specimens were considered microsatellite stable.
The expression of hMSH2, hMSH6, hMLH1, and hPMS2 in the
®ve tumor specimens was examined by immunohistochemistry.
Positive staining for all four proteins was detected in normal
epidermis present in the sections of GR and PR melanomas.
Nuclear immunoreactivity for the MMR proteins was found in
epidermal keratinocytes predominantly in the basal and ®rst one to
three suprabasal cell layers. Single scattered cells positive for
hMSH2, hMLH1, and hPMS2 were also detected in the uppermost
epidermal layers (Fig 4b). Dermal ®broblasts, as well as endothelial
cells of dermal and lymph node vessels and pericytes or smooth
muscle cells in the microvascular wall, showed either no or only
weak immunoreactivity with these MoAb (Fig 4a). Lymphocytes
showed variable immunostaining ranging from negative to strongly
positive labeling (Fig 4a).
Nuclear immunostaining for hMSH2 was present in the vast
majority of neoplastic cells (over 80%) from all ®ve specimens
(Fig 4a, b), and in PR and GR sections the protein expression
appeared upregulated in melanoma cells compared to the neigh-
boring keratinocytes. Expression of hMSH6 was heterogeneous,
and generally present in a lower percentage of nuclei (Fig 4a, b).
The staining patterns of hMLH1 and hPMS2 in CN, CR, GR, and
SN sections were similar to that of hMSH2, with the vast majority
of melanoma cells showing clear nuclear staining (Fig 4a). No
immunoreactivity for either hMLH1 or hPMS2 was found in the
PR specimen (Fig 4b).
DISCUSSION
Determining whether loss of MMR occurs in human melanomas
and whether it is associated with a speci®c MSI phenotype may
have both biologic and clinical relevance. As already demonstrated
for colorectal cancer, loss of MMR might play a role in the etiology
of a subset of melanomas, and the MSI phenotype might be of
prognostic signi®cance and also predictive of tumor responsiveness
to certain chemotherapeutic agents.
This investigation was conducted to better clarify the relation-
ship between MMR defects and MSI in sporadic melanoma.
Although MSI and loss of MMR protein expression (Korabiowska
et al, 2000; Lo Muzio et al, 2000) in melanoma have been
described, no studies are at present available in which both
parameters have been simultaneously evaluated in the same tumor,
or in which the degree of MSI has been correlated with
biochemical evidence of MMR de®ciency.
We used ®ve melanoma cell lines and the corresponding tumor
specimens, which were fully characterized for MMR activity and/
or expression of MMR proteins, as well as for MSI. Of the ®ve cell
lines, four were pro®cient in MMR, whereas one (PR-Mel) was
devoid of this activity and did not express hMLH1 or hPMS2.
To date, loss of hMutLa function in HNPCC or in sporadic
tumors has been principally associated with mutations or epigenetic
silencing (through promoter hypermethylation) of the hMLH1
gene. These tumors invariably lack also hPMS2 as this protein is
unstable in the absence of hMLH1 (Papadopoulos et al, 1994; Ma et
al, 2000). The observed loss of hMutLa expression in PR-Mel is
probably due to inactivation of both hMLH1 alleles. No
hypermethylation of the hMLH1 promoter was found in PR-Mel
cells (data not shown). As shown in Fig 3, however, one allele of
BAT21 (which is located in intron 11 of the hMLH1 gene) is lost in
this cell line, whereas the other displays a size alteration. These
®ndings suggest that a hemizygous mutation in hMLH1 may be
present in the PR-Mel cell line. No germline mutations of hMLH1
were found in the PR patient (data not shown), suggesting that loss
Figure 3. Microsatellite alterations in human
melanoma cell lines and tumor specimens.
For each patient, genomic DNA was extracted
from normal peripheral blood mononuclear cells
(N), the melanoma cell line (L), and the
corresponding tumor specimen (T), and subjected
to PCR ampli®cation with primers speci®c for the
indicated microsatellite loci. The PCR products
were analyzed on a 6% polyacrylamide denaturing
gel. Arrowhead, LOH; angled arrows, MSI.
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of hMLH1 protein expression in PR-Mel occurred through
somatic inactivation of both alleles of hMLH1.
Microsatellite analysis of the ®ve melanoma cell lines revealed
alterations compatible with two different mechanisms, LOH and
MSI. LOH at D11S904 was detected in CN-Mel and SN-Mel, and
LOH at D17S250 was found in GR-Mel. The ®rst microsatellite is
located on 11p13±14, whereas the second is on 17q11.2±12
(Dietmaier et al, 1997). As LOH in the vicinity of these
chromosomal loci has to date not been linked to the pathogenesis
or progression of melanoma, the alterations found in our cell lines
most probably represent random chromosomal aberrations.
MSI was detected in all cell lines with the exception of SN-Mel.
The MMR-pro®cient cells displayed L-MSI, however, being
unstable at only one locus among the mononucleotide markers of
all the repeat tested (Table II). This phenotype could be indicative
of hMSH6 de®ciency, but our results showed that all these lines
expressed normal quantities of this protein. In contrast, the MMR-
de®cient cell line PR-Mel displayed H-MSI (®ve loci unstable out
of 12 examined). This ®nding is consistent with previous reports on
HNPCC and sporadic colorectal tumors demonstrating that the H-
MSI phenotype is associated with the loss of hMSH2, hMLH1, or
hPMS2 expression, whereas the L-MSI phenotype may occur in
tumors carrying no alterations in the known MMR genes. The
CN-Mel, CR-Mel, and GR-Mel cell lines fall into this category, as
they display L-MSI in spite of the normal expression and function
of all four MMR proteins investigated. It has been suggested that
inactivation of the DNA repair enzyme O6-methylguanine-DNA
methyltransferase (MGMT) in colorectal tumors may result in an L-
MSI phenotype (Whitehall et al, 2001). In agreement with this
hypothesis, we found barely detectable MGMT levels in CR-Mel
Figure 4. Immunohistochemical detection of
MMR proteins in human melanoma. (a)
Tumor CR (lymph node metastasis). Nuclear
immunoreactivity for hMSH2, hMLH1, and
hPMS2 is present in the majority of melanoma
cells. A lower number of melanoma cells appears
hMSH6 positive, with differences in staining
intensity. A weak nuclear positivity is visible in
lymphocytes (arrowhead) and endothelial cells
(arrows). (b) Tumor PR (cutaneous metastasis).
The keratinocytes display nuclear immuno-
reactivity for all four MMR proteins. The
melanoma cells show nuclear immunostaining for
hMSH2 and hMSH6 and no expression of
hMLH1 or hPMS2. Scale bar: 50 mm.
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cells (data not shown). Both CN-Mel and GR-Mel cell lines
displayed high MGMT activity, however, thus excluding the
possibility that loss of this enzyme is the underlying cause of their
L-MSI phenotype. It is possible that L-MSI in these MMR-
pro®cient cell lines results from defects in DNA repair genes other
than MGMT or those involved in mismatch repair.
The relationship between loss of MMR and H-MSI was also
con®rmed in the tumor specimens from which the ®ve melanoma
cell lines were derived. Indeed, neither hMLH1 nor hPMS2 were
expressed in the PR tumor (H-MSI phenotype), whereas nuclear
expression of hMSH2, hMLH1, and hPMS2 was observed in the
majority of melanoma cells of tumors CN and CR (L-MSI
phenotype), as well as GR and SN (microsatellite stable
phenotype). Interestingly, immunoreactivity for hMSH6 appeared
heterogeneous among the ®ve melanomas, in terms of both
percentage of positive cells and staining intensity. The molecular
basis of the heterogeneous staining for hMSH6 observed in the
melanoma specimens is at present unknown. It is possible to
speculate, however, that unlike hMSH2, hMLH1, and hPMS2
proteins, whose levels remain relatively constant throughout the
cell cycle (Marra et al, 1996; Meyers et al, 1997), hMSH6 expression
changes (Szadkowski and Jiricny, 2002).
In conclusion our data support the hypothesis that, similarly to
epithelial tumors, two distinct mutator phenotypes can be distin-
guished in melanoma, one that is characterized by H-MSI and
another that shows L-MSI, but that only the former is dependent
on the inactivation of the MMR system. Studies currently in
progress in our laboratory on a large series of tumor specimens aim
to evaluate the frequency of H-MSI and MMR defects in primary
and metastatic melanoma, and to establish whether H-MSI tumors
display different clinical and pathologic features, and potentially
different etiology.
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